We want to thank Huo and Liu [1] for their great interest in our paper [2] and for sharing their data. Indeed, thrombocytosis was repeatedly associated with a worse prognosis in patients with various cancer entities [3, 4]. Prophylactic treatment with acetylsalicylic acid does not only reduce the risk of cancer development [5] but may also reduce the risk of distant metastasis formation [6].
Therefore, we agree that a prospective randomized trial on the additive effect of anti-platelet therapy in patients with hepatocellular carcinoma is eagerly awaited.
